HeTalksFinance@HeTalksFinance
Senores Pharmaceuticals Ltd. (SPL) IPO Overview
About Senores Pharmaceuticals Ltd. (SPL): SPL is a global player in the pharmaceutical industry, specializing in the development and manufacture of a wide array of pharmaceutical products for regulated markets like the US, Canada, and the UK, alongside serving emerging markets in 43 countries. It's known for its capability to identify, develop, and commercialize specialty, underpenetrated, and complex pharmaceutical products, making it a preferred partner for several key players including Prasco LLC, Lannett Company Inc., and Sun Pharmaceuticals. The company's strategic use of data analytics, research, and market assessment allows it to pinpoint commercially viable molecules, ensuring a pipeline of diverse, high-quality products.
Business Model: SPL operates through long-term marketing arrangements (5-7 years) with major pharmaceutical companies, earning revenue via in-licensing fees, transfer prices, and profit sharing. Additionally, it engages in CDMO/CMO activities from its Atlanta Facility, providing services from drug development to commercial manufacturing, which includes partnerships with entities like Mint Pharmaceuticals and Solco Healthcare US LLC.
Issue Details:
IPO Structure: SPL is launching its IPO with a book-building route, offering 14,887,724 equity shares at a price band of ₹372 to ₹391 per share, aiming to raise ₹582.11 crore. This includes a fresh issue of shares worth ₹500 crore and an Offer for Sale (OFS) worth ₹82.11 crore.
Subscription Dates: Open from December 20 to December 24, 2024.
Allocation: 75% to QIBs, 15% to HNIs, 10% to retail, with 75,000 shares reserved for employees.
Use of Proceeds: The funds will be used for investing in subsidiaries (Havix, SPI, Ratnatris), debt repayment, working capital, inorganic growth, and general corporate purposes.
Financial Performance:
Growth: SPL's financials show a significant jump in revenue and profit from FY22 to FY24, with total income increasing from ₹14.63 crore to ₹217.34 crore and net profit from ₹0.10 crore to ₹32.71 crore. For H1 FY25, it reported a net profit of ₹23.94 crore on ₹183.35 crore in income.
Valuations: The IPO is priced at a P/E ratio of 55.07 based on FY24 earnings and 37.60 on annualized FY25 earnings, suggesting an aggressive valuation given the recent financial trajectory.
Margins: PAT margins have fluctuated from 7.00% in FY22 to 15.25% in FY24, with RoCE showing similar volatility.
Dividend Policy: SPL has not paid dividends historically but has recently adopted a policy contingent on financial performance.
Comparison with Listed Peers: While SPL lists companies like Ajanta Pharma and Gland Pharma as peers, the comparison is not direct due to differing business focuses. SPL's P/E ratio appears higher than its peers, indicating a premium pricing.
Merchant Banker’s Track Record: The BRLMs have a mixed record, with about 22% of the IPOs they managed closing below their offer prices on listing.
Conclusion / Investment Strategy:
This IPO presents an opportunity in the pharmaceutical sector with a focus on complex generics, but it comes with considerations around valuation and growth sustainability.
#ipo #ipoallotment #ipoupdate #ipogmp #ipogmpupdate #ipopremium #ipopremiumupdate #IPOListing
